Pharmacokinetics of vincristine sulfate in adult cancer patients
- PMID: 7260915
Pharmacokinetics of vincristine sulfate in adult cancer patients
Abstract
Vincristine concentration in serum from 1 min to 72 hr was measured by radioimmunoassay in 14 patients with cancers following i.v. bolus injection of vincristine sulfate at 0.45 to 1.30 mg/sq m. The pharmacokinetic data were analyzed by a nonlinear least-square regression program NONLIN. A three-compartmental open model fitted the raw data better than a two-compartmental model. The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively. The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively. The plasma clearance was 141.9 ml/min/1.73 sq m, and the area under the concentration X time curve from 0 to infinity (AUC0 infinity) for 2 mg vincristine was 21,689 nM.min. Linear regression analysis of the data gave evidence for increasing plasma clearance at higher doses of vincristine. In patients with higher platelet counts, lower AUC0 infinity values were obtained, suggesting a possible interaction of vincristine with blood platelets. Our results, a large Vdss, a long biological half-life, and a low rate-limiting rate constant from Compartment 3 to the central compartment (k31), indicate an avid tissue binding and a slow drug release from the body tissues which may account for drug-related neurotoxicity.
Similar articles
-
Pharmacokinetics of vincristine sulfate in children.Cancer Chemother Pharmacol. 1981;6(2):111-5. doi: 10.1007/BF00262326. Cancer Chemother Pharmacol. 1981. PMID: 7307229
-
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.Cancer Chemother Pharmacol. 2005 May;55(5):488-96. doi: 10.1007/s00280-004-0900-4. Epub 2005 Feb 23. Cancer Chemother Pharmacol. 2005. PMID: 15726371 Clinical Trial.
-
Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.Cancer Res. 1993 Oct 15;53(20):4843-9. Cancer Res. 1993. PMID: 8402671 Clinical Trial.
-
Is volume of distribution at steady state a meaningful kinetic variable?J Clin Pharmacol. 1983 Aug-Sep;23(8-9):391-400. doi: 10.1002/j.1552-4604.1983.tb02753.x. J Clin Pharmacol. 1983. PMID: 6355205 Review.
-
[Vincristine neuropathy].Naika. 1971;28(3):449-50. Naika. 1971. PMID: 4938362 Review. Japanese. No abstract available.
Cited by
-
Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine.Drug Deliv. 2018 Nov;25(1):398-416. doi: 10.1080/10717544.2018.1431980. Drug Deliv. 2018. PMID: 29378456 Free PMC article. Review.
-
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.Cancer Chemother Pharmacol. 2023 Nov;92(5):391-398. doi: 10.1007/s00280-023-04580-1. Epub 2023 Aug 23. Cancer Chemother Pharmacol. 2023. PMID: 37610625
-
Pharmacokinetics of vincristine sulfate in children.Cancer Chemother Pharmacol. 1981;6(2):111-5. doi: 10.1007/BF00262326. Cancer Chemother Pharmacol. 1981. PMID: 7307229
-
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs.Pharmaceutics. 2019 Mar 7;11(3):110. doi: 10.3390/pharmaceutics11030110. Pharmaceutics. 2019. PMID: 30866479 Free PMC article. Review.
-
Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002. Clin Pharmacokinet. 1983. PMID: 6189661 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials